Taylor Dismuke Selected Research

Brain Neoplasms (Brain Tumor)

1/2022	Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq-guided combination with sapanisertib.
1/2021	Poly(2-oxazoline) nanoparticle delivery enhances the therapeutic potential of vismodegib for medulloblastoma by improving CNS pharmacokinetics and reducing systemic toxicity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Taylor Dismuke Research Topics

Disease

6	Medulloblastoma 12/2023 - 12/2019
4	Neoplasms (Cancer) 06/2023 - 12/2019
2	Brain Neoplasms (Brain Tumor) 01/2022 - 01/2021
1	Basal Cell Carcinoma (Rodent Ulcer) 01/2021

Drug/Important Bio-Agent (IBA)

5	Small Cytoplasmic RNAIBA 06/2023 - 12/2019
3	Mechanistic Target of Rapamycin Complex 1IBA 12/2023 - 01/2021
2	HhAntag691IBA 01/2021 - 12/2019
1	DNA (Deoxyribonucleic Acid)IBA 06/2023
1	Amino Acid Transport System X-AG (Glutamate Transporter)IBA 01/2022
1	sapanisertibIBA 01/2022
1	palbociclibIBA 01/2022
1	poly(2-oxazoline)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 12/2019

Therapy/Procedure

5	Therapeutics 12/2023 - 12/2019